Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxycycline and TUDCA for Transthyretin Amyloidosis
NCT01171859Phase 2Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Jul 2010
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxycycline and tauroursodeoxycholic acid in transthyretin amyloidosis (ATTR), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Response rate to doxycycline + tauroursodeoxycholic acid treatment at 1 year. Started Jul 2010; status: completed.
02
Drugs
doxycyclinetauroursodeoxycholic acid
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT01171859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01171859.